Breaking News

Regeneron Acquires 2seventy Bio Platforms and Preclinical & Clinical Programs

Announces the formation of Regeneron Cell Medicines, a new R&D unit.

Author Image

By: Charlie Sternberg

Associate Editor

Regeneron Pharmaceuticals Inc. has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities.   2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters